Annovis Bio, Inc.

ANVS

Annovis Bio, Inc.

ANVS

Insider Sentiment (TTM):

Last Purchase:2026-05-20Last Sale:-Shares Purchased (TTM):1,982,515Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:4,590,291Shares Outstanding:27,847,884Institutional Ownership Pct.:16.48%

Earnings Market Reaction:

Filing Date:2026-05-15Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	14	20	15	17	22	11	13	4	3	6	6	16
Assets Current	-	-	-	-	-	-	-	-	8	10	10	23
Assets	16	21	17	21	27	14	14	5	8	10	10	23
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	5	3	2	1	1	2	4	3	4	1	2	1
Liabilities Current	13	4	4	3	3	4	5	4	5	4	4	2
Liabilities Noncurrent
Derivative Liabilities Noncurrent	-	-	-	-	-	-	0	1	6	14	-	-
Liabilities	13	4	4	3	3	5	7	7	11	18	4	2
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	184	181	167	165	164	144	136	115	108	103	95	94
Retained Earnings Accumulated Deficit	-181	-164	-154	-147	-140	-135	-129	-116	-111	-110	-88	-73
Stockholders Equity	3	17	13	18	24	9	7	-2	-3	-8	7	21
Liabilities And Stockholders Equity	16	21	17	21	27	14	14	5	8	10	10	23
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	2	2	2	2	2	2	2	2	2	2	2	2
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	70	70	70	70	70	70	70	70	70	70	70	70
Common Stock Shares Issued	29	27	20	19	19	14	13	12	11	11	9	9
Shares Outstanding	29	27	20	19	19	14	13	12	11	11	9	9

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-8.25%	-6.31%	-	-	-	-	-	-	-	-	-	-
2025	88.82%	38.82%	47.65%	-17.33%	-19.86%	-24.19%	87.24%	50.21%	11.11%	-9.52%	-20.63%	-23.81%
2024	10.46%	-2.87%	84.82%	1.42%	8.38%	17.14%	-17.77%	-35.42%	-39.71%	-25.71%	-12.57%	83.43%
2023	-	-	-	-13.07%	-34.04%	-51.60%	52.97%	236.94%	78.56%	-	-	-
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	-	-	-	-	-	-	-	-	1.60	2.39	2.87	11.00
Quick Ratio	-	-	-	-	-	-	-	-	1.60	2.39	2.87	11.00
Working Capital	-	-	-	-	-	-	-	-	2.94M	5.93M	6.66M	20.74M
Leverage & Debt
Debt to Equity	4.20	0.25	0.31	0.17	0.11	0.50	1.03	-3.88	-3.33	-2.32	0.54	0.10
Interest Coverage TTM	-	-	-	-	-968.81	-380.56	-223.09	-144.48	-89.41	-67.43	-62.72	-58.43
Debt Ratio	-	-	-	-	-	-	-	-	1.43	1.76	0.35	0.09
Efficiency & Turnover
Asset Turnover TTM	-	-	-	-	-	-	-	-	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-1.47	-1.40	-1.26	-1.55	-1.67	-2.01	-3.16	-3.80	-4.39	-6.23	-4.63	-3.73
Free Cash Flow Per Share TTM	-0.95	-1.25	-1.27	-1.27	-1.32	-1.80	-1.77	-2.58	-3.33	-4.43	-3.80	-3.22
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	40.82%	17.34%	-39.22%	-29.66%	-38.86%	-56.25%	-1.86%	28.67%	59.34%	121.90%	77.39%	67.72%
EPS Growth (1Y)	-11.85%	-30.45%	-59.93%	-59.18%	-62.73%	-67.59%	-31.84%	1.86%	22.90%	100.73%	60.69%	52.97%
Valuation Metrics
P/E TTM	-1.52	-2.46	-1.64	-1.40	-0.90	-2.49	-2.55	-1.51	-2.66	-3.00	-2.05	-3.83
P/B TTM	19.87	4.22	3.10	2.31	1.09	6.58	14.81	-37.20	-37.70	-21.77	12.85	6.17
Market Cap	62.10M	71.11M	40.75M	42.29M	26.15M	61.28M	104.59M	65.13M	126.44M	168.73M	85.53M	127.91M
Enterprise Value	47.88M	51.58M	25.46M	25.15M	3.91M	50.73M	91.95M	61.13M	123.30M	162.98M	79.17M	112.19M
Calculated Values
Free Cash Flow TTM	-26.53M	-25.62M	-24.98M	-24.69M	-22.96M	-21.89M	-22.97M	-29.14M	-35.37M	-39.97M	-34.21M	-28.83M
Net Debt	-14.22M	-19.53M	-15.29M	-17.13M	-22.24M	-10.55M	-12.64M	-4.00M	-3.14M	-5.75M	-6.35M	-15.72M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-20Purchase

Owner: Hoffman, Michael B

Title: -

Shares: 76,344

Price/Share: $1.82

Value: $138,946.08

Shares Owned: 3,364,883

Relationship: Director

Ownership: Direct

2026-04-02Purchase

Owner: Hoffman, Michael B

Title: -

Shares: 713,800

Price/Share: $2.10

Value: $1,498,980.00

Shares Owned: 3,288,539

Relationship: Director

Ownership: Direct

2025-12-08Purchase

Owner: Hoffman, Michael B

Title: -

Shares: 45,000

Price/Share: $4.29

Value: $193,050.00

Shares Owned: 2,574,739

Relationship: Director

Ownership: Direct

2025-11-24Purchase

Owner: Hoffman, Michael B

Title: -

Shares: 39,200

Price/Share: $4.07

Value: $159,544.00

Shares Owned: 2,529,739

Relationship: Director

Ownership: Direct

2025-11-21Purchase

Owner: Hoffman, Michael B

Title: -

Shares: 20,000

Price/Share: $3.50

Value: $70,000.00

Shares Owned: 2,490,539

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-20	Hoffman, Michael B	Director	-	Direct	Purchase	76,344	1.82	$138,946.08	3,364,883	4
2026-04-02	Hoffman, Michael B	Director	-	Direct	Purchase	713,800	2.10	$1,498,980.00	3,288,539	4
2025-12-08	Hoffman, Michael B	Director	-	Direct	Purchase	45,000	4.29	$193,050.00	2,574,739	4
2025-11-24	Hoffman, Michael B	Director	-	Direct	Purchase	39,200	4.07	$159,544.00	2,529,739	4/A
2025-11-21	Hoffman, Michael B	Director	-	Direct	Purchase	20,000	3.50	$70,000.00	2,490,539	4
2025-11-14	Hoffman, Michael B	Director	-	Direct	Purchase	15,000	2.11	$31,650.00	2,470,539	4
2025-10-28	Maccecchini, Maria-Luisa	Director,Officer	President & CEO	Direct	Purchase	97,561	2.05	$200,000.05	1,212,020	4
2025-10-28	Hoffman, Michael B	Director	-	Direct	Purchase	975,610	2.05	$2,000,000.50	2,455,539	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

16.48%

Inst. Shares: 4,590,291

Shares Outstanding: 27,847,884

2025-12-31

20.27%

Inst. Shares: 4,164,960

Shares Outstanding: 20,551,997

2025-09-30

9.81%

Inst. Shares: 1,930,987

Shares Outstanding: 19,685,071

2025-06-30

8.97%

Inst. Shares: 1,748,293

Shares Outstanding: 19,486,231

2025-03-31

11.58%

Inst. Shares: 2,018,768

Shares Outstanding: 17,431,234

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	4,590,291	27,847,884	16.48%
2025-12-31	4,164,960	20,551,997	20.27%
2025-09-30	1,930,987	19,685,071	9.81%
2025-06-30	1,748,293	19,486,231	8.97%
2025-03-31	2,018,768	17,431,234	11.58%
2024-12-31	1,544,491	12,182,475	12.68%
2024-09-30	1,153,972	12,975,808	8.89%
2024-06-30	969,243	11,307,759	8.57%
2024-03-31	1,199,044	10,625,065	11.29%
2023-12-31	1,192,829	9,023,138	13.22%
2023-09-30	1,110,618	9,012,273	12.32%
2023-06-30	1,278,591	8,951,309	14.28%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Annovis Bio, Inc. (ANVS) — SEC Financial Statements & Analysis

Annovis Bio, Inc. (ANVS) is a pharmaceutical preparations company, incorporated in DE. Annovis Bio, Inc. trades on NYSE as: ANVS. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Annovis Bio, Inc. reported a Debt-to-Equity ratio of 4.20x, a Price-to-Book (P/B) ratio of 19.87 (TTM), at a market cap of $62.10M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 4.20x
P/B TTM: 19.87
Market Cap: $62.10M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Annovis Bio, Inc. in?

Annovis Bio, Inc. (ANVS) operates in the Pharmaceutical Preparations industry.

What is ANVS's market cap?

Annovis Bio, Inc. (ANVS) has a market capitalization of $62.10M as of 2026-03-31.

What exchange does ANVS trade on?

Annovis Bio, Inc. (ANVS) trades on the NYSE.

Where is Annovis Bio, Inc. incorporated?

Annovis Bio, Inc. is incorporated in DE.

Annovis Bio, Inc. (ANVS) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.